logo
logo
SIGNAL-DRIVEN SALES

Act on Executive-Hire Signals First

Track leadership moves and score urgency so you reach new decision-makers during their evaluation window.

10–25 decision-maker leads daily • First-90-days targeting • Intent scoring
Every plan includes:
✓Signal-Driven Leads Based on YOUR ICP
✓Role-aware buyer intent scoring
✓Direct outreach workflows
INDUSTRY FIRST

Alpine Immune Sciences (Alpn) Appoints Wolfgang Dummer As Chief Medical Officer

Oct 04, 2023•almost 2 years ago

Position

Chief Medical Officer

Company

Alpine Immune Sciences

Wolfgang Dummer
SeattleBiotechnology

Description

Alpine Immune Sciences, Inc. today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, M.D., who will transition responsibilities to Dr

Company Information

Company

Alpine Immune Sciences

Location

Seattle, Washington, United States

About

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.

Company News

(8 articles)
Thu, 07 Mar 2024 08:00:00 GMT

Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results - Business Wire

Wed, 10 Apr 2024 07:00:00 GMT

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Business Wire

Thu, 02 Nov 2023 07:00:00 GMT

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 | FinancialContent - FinancialContent

Mon, 26 Feb 2024 08:00:00 GMT

Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences - Business Wire

Thu, 21 Mar 2024 07:00:00 GMT

Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 - Business Wire

Mon, 18 Mar 2024 07:00:00 GMT

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results - Business Wire

Wed, 10 Apr 2024 07:00:00 GMT

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy - Business Wire

Thu, 21 Dec 2023 08:00:00 GMT

Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie - Business Wire

FundzWatch™ Score

85
Medium Activity

Related People

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months